Patient portal

ASC4KIDS-2 (Chronic myeloid leukemia)

Clinical study to evaluate the safety and efficacy of the drug asciminib in pediatric and adolescent participants who are recently newly diagnosed or previously treated and who have Philadelphia positive Chronic Myeloid Leukemia (CML) in Chronic Phase with or without known T315I mutation. 

Recruiting

Who can enter

  • Children who are recently newly diagnosed with chronic myeloid leukemia (CML) or who have been previously treated for CML

  • Age: 1 year to <18 year

Goal

The goal of this study is to learn more about the effects of asciminib in children and adolescents with CML. We are testing asciminib in children and adolescents with chronic myeloid leukemia who have recently been diagnosed or who have been treated previously.

Background

At this moment, there is no suitable treatment specifically for children with Philadelphia-positive chronic myeloid leukemia in the chronic phase, with or without a known T315I mutation. That is why we want to investigate whether this treatment with asciminib is effective.

Asciminib is a so-called tyrosine kinase inhibitor. These are medicines that target the BCR-ABL1 protein. This protein is produced by the BCR-ABL gene. BCR-ABL1 stimulates the growth of leukemia cells. Asciminib binds to a specific part of the BCR-ABL1 protein and thereby blocks its function. As a result, the growth of the leukemia cells can be stopped.

We want to determine how asciminib works and how safe it is.

Participation in the study lasts approximately 4 to 7 years. During the study, several additional tests and assessments will be performed that differ from standard care. For example, a bit more blood or bone marrow will be collected. We will also perform electrocardiograms (ECGs) more frequently.

The drug is not yet approved for the treatment of CML in children. However, it has already been approved as a treatment for adults with CML.

In order to participate in a study please refer to your/your child’s doctor.

Last reviewed

August 24, 2026

Study details

The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.